BACKGROUND: Some ganglioside complexes (GSCs) are target antigens for serum antibodies in patients with Guillain-Barré syndrome (GBS). Anti-GSC antibodies may be associated with particular clinical features of GBS. OBJECTIVE: To investigate antibodies to GSCs in the sera of patients with Miller Fisher syndrome (MFS) characterised by elevation of the IgG anti-GQ1b antibody. RESULTS: In all, 7 of 12 (58%) consecutive patients with MFS were found to have IgG antibodies to GSCs containing GQ1b, of whom 5 had IgG antibodies to GQ1b-GM1 complex (GQ1b/GM1) and 2 had antibodies to GQ1b/GD1a; 4 of 5 patients without sensory symptoms had anti-GQ1b/GM1 antibodies. CONCLUSIONS: At least three different specificities in MFS-associated antibodies, GQ1b-specific, anti-GQ1b/GM1-positive and anti-GQ1b/GD1a-positive, were observed. In patients with MFS not only GQ1b itself but also clustered epitopes of GSCs, including GQ1b, may be considered to be prime target antigens for serum antibodies. A tendency to escape sensory disturbances is shown by anti-GQ1b/GM1-positive MFS.
BACKGROUND: Some ganglioside complexes (GSCs) are target antigens for serum antibodies in patients with Guillain-Barré syndrome (GBS). Anti-GSC antibodies may be associated with particular clinical features of GBS. OBJECTIVE: To investigate antibodies to GSCs in the sera of patients with Miller Fisher syndrome (MFS) characterised by elevation of the IgG anti-GQ1b antibody. RESULTS: In all, 7 of 12 (58%) consecutive patients with MFS were found to have IgG antibodies to GSCs containing GQ1b, of whom 5 had IgG antibodies to GQ1b-GM1 complex (GQ1b/GM1) and 2 had antibodies to GQ1b/GD1a; 4 of 5 patients without sensory symptoms had anti-GQ1b/GM1 antibodies. CONCLUSIONS: At least three different specificities in MFS-associated antibodies, GQ1b-specific, anti-GQ1b/GM1-positive and anti-GQ1b/GD1a-positive, were observed. In patients with MFS not only GQ1b itself but also clustered epitopes of GSCs, including GQ1b, may be considered to be prime target antigens for serum antibodies. A tendency to escape sensory disturbances is shown by anti-GQ1b/GM1-positive MFS.
Authors: G M O'Hanlon; J J Plomp; M Chakrabarti; I Morrison; E R Wagner; C S Goodyear; X Yin; B D Trapp; J Conner; P C Molenaar; S Stewart; E G Rowan; H J Willison Journal: Brain Date: 2001-05 Impact factor: 13.501
Authors: Susan K Halstead; Graham M O'Hanlon; Peter D Humphreys; Deborah B Morrison; Bryan P Morgan; Andrew J Todd; Jaap J Plomp; Hugh J Willison Journal: Brain Date: 2004-08-02 Impact factor: 13.501
Authors: Peggy C R Godschalk; Mark L Kuijf; Jianjun Li; Frank St Michael; C Wim Ang; Bart C Jacobs; Marie-France Karwaski; Denis Brochu; Ali Moterassed; Hubert P Endtz; Alex van Belkum; Michel Gilbert Journal: Infect Immun Date: 2007-01-29 Impact factor: 3.441
Authors: Kay N Greenshields; Susan K Halstead; Femke M P Zitman; Simon Rinaldi; Kathryn M Brennan; Colin O'Leary; Luke H Chamberlain; Alistair Easton; Jennifer Roxburgh; John Pediani; Koichi Furukawa; Keiko Furukawa; Carl S Goodyear; Jaap J Plomp; Hugh J Willison Journal: J Clin Invest Date: 2009-02-16 Impact factor: 14.808
Authors: Simon Rinaldi; Kathryn M Brennan; Carl S Goodyear; Colin O'Leary; Giampietro Schiavo; Paul R Crocker; Hugh J Willison Journal: Glycobiology Date: 2009-04-06 Impact factor: 4.313
Authors: Zhahirul Islam; Michel Gilbert; Quazi D Mohammad; Kevin Klaij; Jianjun Li; Wouter van Rijs; Anne P Tio-Gillen; Kaisar A Talukder; Hugh J Willison; Alex van Belkum; Hubert P Endtz; Bart C Jacobs Journal: PLoS One Date: 2012-08-27 Impact factor: 3.240